Removal of Complex Renal Tumors Performed Safely by Robotic Surgery in Selected Patients

Robotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes and reproducibility when performed by surgeons with adequate robotic experience, according to first multi-institutional report, published in The Journal of Urology®

New York, NY February 7, 2016

Renal cell carcinoma can sometimes spread to the inferior vena cava (IVC), the body’s largest vein, posing a threat to the heart and brain. Robotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes in selected patients compared with open surgery, which can have a high rate of complications, report surgeons in The Journal of Urology®.

Renal vein surgery can often be managed with minimally invasive laparoscopic techniques, but this is not typically advisable for an IVC thrombus (a fibrous clot), which is surgically far more complex with potentially fatal complications that can occur in the course of removing the thrombus and reconstructing the IVC.

The first known procedure using robotic surgery of renal tumors with IVC tumor thrombi was performed in 2008. Experts from nine leading U.S. medical centers report here on their combined experience of 32 cases since 2008.  Each surgeon performed between one and ten procedures for IVC tumor thrombi which ranged from one to 11 cm in length on preoperative imaging. Patient age ranged from 43 to 80 years.

The IVC required cross-clamping in 24 cases. One patient had two renal veins with two caval thrombi and one patient required a synthetic patch. Surgeries lasted from three to seven hours. None of the operations was converted to open surgery and all but two patients were ambulatory on the day of or day after surgery. Twenty-one patients resumed regular diets the day after surgery. Eight patients had node positive disease and seven patients had distant recurrence 15 months later including four of those with node positive disease.

“This is a complex condition and the complication rate with open surgery is 12% to 47%, depending on the thrombus level, with a mortality rate of 5% to 10%,” explained lead investigator Ronney Abaza, MD, Robotic Surgery Director at OhioHealth Dublin Methodist Hospital. “Using robotic nephrectomy, our complication rate and lack of mortalities compare reasonably with open series with no grade III to V complications, according to the Clavien system, in any patient, including no deaths.”

Dr Abaza added, “While complications were relatively minor in our series, it is evident that complications are not entirely avoidable. Even with a minimally invasive approach, the surgical management of severe cancers in mostly elderly patients will likely involve complications. However, despite the complex and critical nature of these procedures, our series demonstrates favorable outcomes and reproducibility by surgeons with adequate robotic experience.”


Notes for Editors
“Multi-Institutional Experience with Robotic Nephrectomy with IVC Tumor Thrombectomy,” by Ronney Abaza, Ahmad Shabsigh, Erik Castle, Mohamad Allaf, Jim C. Hu, Craig Rogers, Mani Menon, Monish Aron, Chandru P. Sundaram, and Daniel Eun, DOI: The Journal of Urology®, published online in advance of Volume 195, Issue 4 (April 2016), published by Elsevier.

Full text of this article is available to credentialed journalists upon request; contact Eileen Leahy at +1 732 238 3628 or to obtain copies. Journalists wishing to interview the authors should contact Ronney Abaza at

About The Journal of UROLOGY®
Established in 1917, The Journal of Urology® is the official journal of the American Urological Association. It is the most widely read and highly cited journal in the field. It brings to its readership all the clinically relevant information needed to stay at the forefront of this dynamic field. This top-ranking journal presents investigative studies on critical areas of research and practice, survey articles providing short condensations of the best and most important urology literature worldwide and practice-oriented reports on interesting clinical observations.

About the American Urological Association
Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 22,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

Media contact
Eileen Leahy
+1 732 238 3628